Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

Despite the benefits of such medicines, like Wegovy, Saxenda and Zepbound, many people who could most benefit from them can’t ...

While all state Medicaid programs cover GLP-1 agonists for type 2 diabetes, it’s much less common for them to cover the drugs ...

Most U.S. states do not currently cover highly sought after weight-loss drugs from Novo Nordisk and Eli Lilly in their ...

The National Institute for Health and Care Excellence (NICE), which decides what drugs are available on the NHS, will rule ...

Food naturally boosts your body’s GLP-1 levels, explained Dr. Sun Kim, an endocrinologist at Stanford Health Care in ...

Currently, financial markets are experiencing a mix of optimism and caution as investors react to changing economic ...

The retrospective study points to fewer suicidal thoughts or attempts among adolescents taking semaglutide or liraglutide.

Amid ongoing legal battles over coveted GLP-1 therapies, a drug vendor in Washington state is accused of running an ...

Structure Therapeutics has the potential to have a best-in-class GLP-1 agonist drug for treatment of patients with obesity. Learn more on GPCR stock here.

Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.